61 Advances in skin cancer research highlight the development of personalised risk assessment tools, promising to enhance early detection and prevention. As the incidence of skin cancer continues to rise globally, researchers are leveraging data-driven models to better identify at-risk individuals. The findings were published in the journal Cancers. Skin cancer remains the most common malignancy worldwide, predominantly affecting populations with lighter skin tones. Prolonged exposure to ultraviolet (UV) radiation from natural and artificial sources is the leading preventable risk factor. However, genetic predisposition also plays a significant role. Recent innovations have focused on creating personalised risk scores by integrating genetic, environmental, and behavioural data. One such development is the Disease Risk Score Algorithm (DRSA), a predictive tool combining genetic markers with lifestyle factors. Designed to assess risks for melanoma, basal cell carcinoma, and squamous cell carcinoma, the DRSA has shown promise in identifying high-risk individuals, particularly those predisposed to severe and recurrent forms of skin cancer. This tool could guide targeted prevention strategies, such as routine screenings and personalised monitoring programmes. Additionally, advancements have addressed specific vulnerable groups, including solid organ transplant recipients. These patients are significantly more likely to develop non-melanoma skin cancers due to immunosuppression. To aid in early detection, the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) has been developed, assigning weighted risk scores based on factors such as age, race, and medical history. Its effectiveness in both American and European populations underscores its potential in reducing morbidity among transplant recipients. Despite these innovations, the challenge lies in validation and implementation. Overdiagnosis and overtreatment are ongoing concerns, particularly when screening low-risk individuals. By refining predictive models and ensuring their broad applicability, researchers aim to balance early detection with minimising unnecessary interventions. The evolution of risk assessment tools reflects a shift towards precision medicine in oncology. By empowering individuals to understand their unique risks, these tools pave the way for more effective prevention and treatment strategies in combating skin cancer.